Page 68 - e-CPG-SLE-8_5_24
P. 68

Management of Systemic Lupus Erythematosus

           92.  Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific
               marker  for  diagnosing  bacterial  infections  in  systemic  lupus  erythematosus
               compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012;39(4):728-734.
           93.  Jung JY, Choi ST, Park SH, et al. Prevalence of osteoporosis in patients with
               systemic lupus erythematosus: A multicenter comparative study of the World
               Health  Organization  and  fracture  risk  assessment  tool  criteria.  Osteoporos
               Sarcopenia. 2020;6(4):173-178.
           94.  Ballocca F, D’Ascenzo F, Moretti C, et al. Predictors of cardiovascular events
               in patients with systemic lupus erythematosus (SLE): a systematic review and
               meta-analysis. Eur J Prev Cardiol. 2015;22(11):1435-1441.
           95.  Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic
               lupus:  an  updated  international  multi-centre  cohort  study.  J  Autoimmun.
               2013;42:130-135.
           96.  Clarke AE, Pooley N, Marjenberg Z, et al. Risk of malignancy in patients with
               systemic  lupus  erythematosus:  Systematic  review  and  meta-analysis.  Semin
               Arthritis Rheum. 2021;51(6):1230-1241.
           97.  Yeo  J,  Seo  MS,  Hwang  IC,  et  al.  An  Updated  Meta-analysis  on  the  Risk  of
               Urologic Cancer in Patients with Systemic Lupus Erythematosus. Arch Iran Med.
               2020;23(9):614-620.
           98.  Schmajuk G, Yazdany J. Drug monitoring in systemic lupus erythematosus: a
               systematic review. Semin Arthritis Rheum. 2011;40(6):559-575.
           99.  Gladman DD, Ibanez D, Ruiz I, et al. Recommendations for frequency of visits to
               monitor systemic lupus erythematosus in asymptomatic patients: data from an
               observational cohort study. J Rheumatol. 2013;40(5):630-633.
           100. Tektonidou  MG,  Andreoli  L,  Limper  M,  et  al.  EULAR  recommendations  for
               the  management  of  antiphospholipid  syndrome  in  adults.  Ann  Rheum  Dis.
               2019;78(10):1296-1304.
           101. Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies
               in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84.
           102. Cervera  R,  Piette  JC,  Font  J,  et  al.  Antiphospholipid  syndrome:  clinical  and
               immunologic manifestations and patterns of disease expression in a cohort of
               1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027.
           103. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international
               cohorts  further  confirms  the  efficacy  of  aspirin  for  the  primary  prevention  of
               thrombosis  in  patients  with  antiphospholipid  antibodies.  Autoimmun  Rev.
               2015;14(3):192-200.
           104. Ministry of Health Malaysia. Perinatal Care Manual. 4th ed. Putrajaya: MOH;
               2021.
           105. He WR, Wei H. Maternal and fetal complications associated with systemic lupus
               erythematosus:  An  updated  meta-analysis  of  the  most  recent  studies  (2017-
               2019). Medicine (Baltimore). 2020;99(16):e19797.
           106. McDonald EG, Bissonette L, Ensworth S, et al. Monitoring of Systemic Lupus
               Erythematosus  Pregnancies:  A  Systematic  Literature  Review.  J  Rheumatol.
               2018;45(10):1477-1490.
           107. Shaharir  SS,  Maulana  SA,  Shahril  NS,  et  al.  Adverse  pregnancy  outcomes
               among multi-ethnic systemic lupus erythematosus patients in Malaysia. Lupus.
               2020;29(10):1305-1313.
           108. Ferguson S, Trupin L, Yazdany J, et al. Who receives contraception counseling
               when  starting  new  lupus  medications?  The  potential  roles  of  race,  ethnicity,
               disease activity, and quality of communication. Lupus. 2016;25(1):12-17.
           109. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive
               methods  in  women  with  systemic  lupus  erythematosus.  N  Engl  J  Med.
               2005;353(24):2539-2549.

                                      51
   63   64   65   66   67   68   69   70   71   72   73